IP Library Patent Application 18088286
Patent Application
App. No. 18/088,286

SOLID STATE FORMS OF FUSED HETEROAROMATIC PYRROLIDINONES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/088,286
Abstract

Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.

Claims (15)

1 . A compound which is 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one citrate.

2 . The compound of claim 1 , which is substantially crystalline.

3 - 7 . (canceled)

8 . A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable carriers.

9 - 11 . (canceled)

12 . A method of treating a cancer comprising administering to a subject having a cancer a compound of claim 1 .

13 - 14 . (canceled)

15 . The method of claim 12 , wherein the cancer is selected from indolent non-Hodgkin’s lymphoma (iNHL), peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), nasopharyngeal carcinoma, gastric carcinoma, breast cancer, ovarian cancer, lung cancer and a post-transplant lymphoproliferative disorder (PT-LPD).

16 - 26 . (canceled)

27 . A method of making 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one or a pharmaceutically acceptable salt thereof, comprising deprotecting a compound of Formula VI

or a pharmaceutically acceptable salt thereof, wherein R

3 and R 4 are each independently protecting groups or R 3 and R 4 together are a protecting group and R 5 and R 6 are each independently a protecting group, under deprotecting conditions.

28 . A compound of Formula VI

or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt thereof, wherein R

3 and R 4 are each independently protecting groups or R 3 and R 4 together are a protecting group and R 5 and R 6 are each independently a protecting group.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2023
From: CALITHERA BIOSCIENCES, INC.
To: WELLS THERAPEUTICS, INC.
Reel/Frame 063837/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2023
From: ICHIBAKASE, TOMONORI; MOTOYOSHI, HAJIME; YAJI, KENTARO; YOSHIKAWA, NAOKI
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 062345/0113 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2023
From: CHEN, RONGLIANG; MA, CHUNRONG; MATTHEWS, CHRISTOPHER F.; O'BRYAN, COLIN
To: TAKEDA CALIFORNIA, INC.
Reel/Frame 062345/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2023
From: TAKEDA CALIFORNIA, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 062345/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2023
From: TAKEDA PHARMACEUTICAL COMPANY LIMITED
To: CALITHERA BIOSCIENCES, INC.
Reel/Frame 062345/0148 →